<DOC>
	<DOCNO>NCT00030576</DOCNO>
	<brief_summary>RATIONALE : Biological therapy erlotinib may interfere growth tumor cell slow growth tumor . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining erlotinib cisplatin may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness combine erlotinib cisplatin treat patient recurrent metastatic head neck cancer .</brief_summary>
	<brief_title>Erlotinib Cisplatin Treating Patients With Recurrent Metastatic Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine objective response rate patient recurrent metastatic squamous cell cancer head neck treat erlotinib cisplatin . - Determine stable disease rate , duration response , progression-free survival , median survival , overall survival patient treat regimen . - Determine safety tolerability regimen patient . - Determine relationship clinical , pharmacokinetic , pharmacodynamic effect regimen patient . - Correlate baseline post-treatment level epidermal growth factor receptor , downstream signal component , marker angiogenesis apoptosis tumor skin biopsy clinical outcome patient treat regimen . OUTLINE : This dose-escalation , multicenter study . Patients receive oral erlotinib daily day -6 21 first course cisplatin IV 60 minute day 1 . For second subsequent course , patient receive oral erlotinib daily day 1-21 cisplatin course 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients stable respond disease 6 course may continue receive erlotinib alone disease progression . Cohorts 3-6 patient receive escalate dos erlotinib cisplatin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . At least 6 patient treated MTD . Patients follow every 3 month . PROJECTED ACCRUAL : A maximum 43 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma head neck All primary site , include oral cavity , oropharynx , nasopharynx , hypopharynx , larynx , paranasal sinus Recurrent , unresectable , and/or metastatic disease At least 1 measurable lesion At least 20 mm conventional technique OR least 10 mm spiral CT scan Lesions accessible biopsy Tumor specimen available evaluation epidermal growth factor receptor ( EGFR ) expression No known brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 OR Karnofsky 60100 % Life expectancy : More 12 week Hematopoietic : WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.25 time upper limit normal ( ULN ) AST ALT great 2.5 time ULN Renal : Creatinine normal OR Creatinine clearance least 60 mL/min Cardiovascular : No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Gastrointestinal : No gastrointestinal tract disease result malabsorption No requirement IV alimentation No active peptic ulcer disease Inability swallow tablet siliconbased Gtubes allow Ophthalmic : No abnormality cornea base history ( e.g. , dry eye syndrome Sjogren 's syndrome ) No congenital abnormality ( e.g. , Fuch 's dystrophy ) No abnormal slitlamp examination use vital dye ( e.g. , fluorescein BengalRose ) No abnormal corneal sensitivity test ( e.g. , Schirmer test similar tear production test ) Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 5 year except carcinoma situ cervix , nonmelanoma skin cancer , second primary squamous cell cancer originate head neck No grade 2 great residual ototoxicity neuropathy prior platinumbased therapy No significant traumatic injury within past 21 day No concurrent uncontrolled illness No ongoing active infection No psychiatric illness social situation would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy recurrent metastatic disease Prior platinumbased chemotherapy radiotherapy platinumbased induction chemotherapy allow At least 6 month since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : See Chemotherapy At least 4 week since prior radiotherapy ( except lowdose , limitedfraction palliative nonmyelosuppressive radiotherapy [ e.g. , involve less 20 % function bone marrow use 800 cGy 1 fraction 2,000 cGy 5 fraction ] ) recover No prior radiotherapy target lesion unless evidence disease progression Surgery : See Disease Characteristics At least 21 day since prior major surgery No prior surgical procedure affect gastrointestinal absorption Other : No prior EGFRtargeting therapies No prior investigational agent recurrent metastatic disease No concurrent combination antiretroviral therapy HIV infection No concurrent investigational agent No concurrent anticancer treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>neck cancer occult primary squamous carcinoma</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma sinus nasal cavity</keyword>
</DOC>